Liver Failure

The Dialive device significantly reduced severity of endotoxemia and improved albumin function in patients with acute-on-chronic liver failure and appears safe with careful patient monitoring, according to data in the Journal of Hepatology.

CHICAGO — In a Healio video exclusive, Sarah Khan, MD, explains that patients with advanced liver disease and concurrent fungal infection had worse acute-on-chronic liver failure and higher mortality than those with bacterial infection.

CHICAGO — Researchers reported a 262% increase in liver transplantation for acute-on-chronic liver failure in older patients from 2005 to 2021, with alcohol-related liver disease becoming the leading cause during the COVID-19 pandemic.

A 2011 FDA mandate, which limited acetaminophen dosage to 325 mg/tablet in prescription acetaminophen and opioid products, correlated with a decrease in yearly hospitalizations and cases of acute liver failure related to toxicity.

An FDA mandate limiting acetaminophen in medications combining acetaminophen and opioids was associated with a reduction in serious liver injuries, a recent study in JAMA found.

WASHINGTON — Although adenovirus infection has been widely implicated in an outbreak of acute, severe hepatitis in children, data presented at The Liver Meeting found no “singular definitive etiology” for these cases.

WASHINGTON — The Multi-Organ Dysfunction and Evaluation for Liver transplantation, or MODEL, score predicted high probability of mortality in transplant patients with severe acute-on-chronic liver failure, according to research.

Machine learning models, compared with traditional models, demonstrated good performance in the prediction of short-term prognosis following liver transplant in patients with acute-on-chronic liver failure, according to research.

The ACG published guidelines for the preferred management of acute-on-chronic liver failure, which has emerged as a major cause of mortality worldwide, in the American Journal of Gastroenterology.

The FDA cleared an investigational new drug application for LYG-LIV0001, an allogeneic hepatocyte transplantation solution for end-stage liver disease, according to the agent’s manufacturer.